

****Published December 2015****

MarketVIEW: Helicobacter pylori vaccines (CAT: VAMV065)

Product Name	:	MarketVIEW: Helicobacter pylori vaccines
Description	:	Vaccine opportunity assessment
Contents	:	Executive presentation (.pdf) and forecast models (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	December 2015
Catalogue No	:	VAMV065

Background

Helicobacter pylori (*H.pylori*) is one of world's most common infections with approximately half to two thirds of the world's population harbouring the bacterium. *H.pylori*, which colonizes the human stomach mucosa, can cause active, chronic persistent and atrophic gastritis in adults and children. The bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric cancers. Gastric cancer is the third most common cause of cancer-related deaths in the world, killing approximately 723,000 people in 2012.

H.pylori infection can be eradicated by use of antibiotics and proton-pump inhibitor (PPI) therapy. However, the therapy can be demanding in terms of patient compliance and its effectiveness is impacted by antibiotic resistance. Around 20% of patients fail first line therapy and re-infection is common. Importantly, individuals are only treated on presentation with symptoms because a population wide eradication program is unfeasible. Many investigators have attempted to develop both *H.pylori* therapeutic and prophylatic vaccines with little clinical success. However, an oral urease vaccine was approved in China in 2009 after showing efficacy in Phase III studies in children¹.

The **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value *H.pylori* prophylatic and therapeutic vaccines across relevant markets to 2035. Each model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/Hi forecast scenarios are included based upon the amount of countries targeted by a potential prophylatic vaccine. The therapeutic vaccine model focuses on new and ever (recurrent cases) of peptic ulcer disease.

¹ Zeng M et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2015. Volume 386, No. 10002, p1457–1464, 10 October 2015

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to helicobacter pylori, peptic ulcer disease, gastric cancer and related indications. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel bacterial vaccines has also been utilised.

PRODUCT CONTENTS:

Published December 2015 (CAT No: VAMV065)

****This product is composed of **two** forecast models (.xls)² and a summary presentation (.pdf)

Title page
Author's note
Contents
Executive summary
H.pylori prophylatic vaccine: revenues per scenario to 2035 (\$ 000s)
H.pylori prophylatic vaccine: volumes per scenario to 2035 (000s)
H.pylori prophylatic vaccine: revenues - China and Japan (\$ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 (\$ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 (\$ 000s)
H.pylori therapeutic vaccine: revenues to 2035 (\$ 000s) new cases
H.pylori therapeutic vaccine: revenues to 2035 (\$ 000s) ever cases
H.pylori: Epidemiology and general disease background
The pathogen
H.pylori: epidemiologic burden
H.pylori: epidemiologic burden (Western countries)
United States: seroprevalence of H.pylori
H.pylori: global prevalence map
H.pylori - trends in epidemiology
What is the outcome of H.pylori infection?
What is the outcome of H.pylori infection?
Natural history of H.pylori infection
H.pylori - molecular pathogenesis
H.pylori - mechanism of tumorigenesis
Diagnosis of H.pylori infection
H.pylori and gastric cancer: general background
Gastric Cancer Estimated Incidence, Worldwide in 2012: Men
Gastric cancer: incidence rates per top 20 countries, 2012
Gastric cancer: focus countries - China and Japan
Trends in incidence of stomach cancer in selected countries: age-standardised rate per 100,000, men
H.pylori and non cardia gastric cancer and CagA strains
Global distribution of cag pathogenicity island
Major outcome: peptic ulcer disease
Peptic ulcer disease and H.pylori infection

² Model contents available upon application

Continued.....

Diagnosis of H.pylori infection
Indications for H.pylori treatment
Treatment of H.pylori infection
First-Line Regimens for H.pylori eradication
H.pylori treatment: understanding patient flow (PUD)
H.pylori and antibiotic resistance, other factors
H.pylori and antibiotic resistance (developing world)
Economic burden of Gastrointestinal diseases
Peptic ulcer disease: pharmaceuticals market value (2017)
H.pylori eradication therapy: global market value 2005
H.pylori - other disease outcomes
H.pylori vaccine development
History of R&D approaches and current status
The medical need for a H.pylori vaccine
Notable challenges to H.pylori vaccine development
History of H.pylori vaccine development (preclinical)
Potential H.pylori vaccine antigens (preclinical studies)
H.pylori vaccines: past human studies
Clinical trials for vaccine efficacy against H.pylori: summary
H.pylori vaccine: Chinese study - Chong Qing Kang Wei (CQKW)
H.pylori vaccine (CQKW): - Phase III data
CQKW vaccine - a major advance?
CQKW vaccine: potential obstacles for Western use
CQKW vaccine - current status
H.pylori vaccines - other R&D approaches (ImevaX GmbH)
H.pylori vaccines - other R&D approaches (AMRIC - Canada)
H.pylori vaccines - other R&D approaches (EpiVax)
The cost effectiveness of a H.pylori vaccine
H.pylori vaccines: modelling commercial potential
Broad target populations for a H.pylori vaccine (PX & TX)
Drivers and resistors to prophylatic vaccine (PX)
Drivers and resistors to therapeutic vaccine (TX)
H.pylori vaccines: Target Product Profiles (TPPs)
Modelling methodology: prophylatic vaccine (PX)
PX vaccine: hypothetical launch sequence
PX vaccine: hypothetical launch sequence: LO scenario
PX vaccine: hypothetical launch sequence: Base scenario
PX vaccine: hypothetical launch sequence: HI scenario
PX vaccine: predicted vaccine coverage (< 1yrs)
PX vaccine: predicted vaccine coverage (preadolescence)
PX vaccine: pricing estimates - guiding assumptions
PX vaccine: pricing estimates – summary
H.pylori therapeutic vaccine (PX): vaccine positioning
Modelling methodology: therapeutic vaccine (TX)
Peptic ulcer disease patient segmentation
Modelling new PUD cases (TX vaccine)
Modelling recurrent ever cases (TX vaccine)
TX vaccine: other modelling assumptions
TX vaccine: potential upsides
Bibliography

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$9995.00**/ GBP **£6665.00**# (Region license)*

Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Helicobacter pylori. CDC Fact Sheet. Available at: <http://www.cdc.gov/ulcer/hpfacts.PDF>. Accessed October 2015
2. World Gastroenterology Organisation Global Guidelines. Helicobacter pylori in developing countries. Available at: <http://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2010.pdf>. Accessed November 2015
3. Parsonnet J, Blaser MJ, Perez-Perez GI, et al. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. *Gastroenterology* 1992;102:41–6. 3.
4. Cullen DJ, Collins BJ, Christiansen KJ, et al. When is Helicobacter pylori infection acquired? *Gut* 1993;34:1681–2. 4.
5. Sipponen P, Kosunen TU, Samloff IM, et al. Rate of Helicobacter pylori acquisition among Finnish adults: a fifteen year follow-up. *Scand J Gastroenterol* 1996;31: 229–32.
6. Everhart JE. Seroprevalence and Ethnic Differences in Helicobacter pylori Infection among Adults in the United States. *J Infect Dis.* (2000) 181 (4): 1359-1363
7. Staat MA et al. A population-based serologic survey of *Helicobacter pylori* infection in children and adolescents in the United States. *J Infect Dis* 1996;174:1120-3.
8. Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori-related disease: Guidelines for testing and treatment. *Arch Intern Med* 2000;160:1285–91
9. Shi R et al. Prevalence and risk factors for Helicobacter pylori infection in Chinese populations. *Helicobacter.* 2008 Apr; 13 (2): 157-65
10. Frenck RW Jr, Clemens J. Helicobacter in the developing world. *Microbes Infect* 2003;5:705–13.
11. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. *Am J Gastroenterol* 2005;100:2083–99.
12. Parsonnet J. What is the Helicobacter pylori global reinfection rate? *Can J Gastroenterol* 2003;17(Suppl B):46B–8B.
13. International Agency for Research on Cancers. Monographs on the evaluation of carcinogenic risks to human Geneva, WHO, 1994:61
14. Suerbaum et al. Helicobacter pylori infection. *N.Eng J Med* 2002; 347: 1175
15. Kusters JG et al. Pathogenesis of Helicobacter pylori infection. *CLINICAL MICROBIOLOGY REVIEWS*, July 2006, p. 449–490
16. Robinson K et al. The inflammatory and immune response to Helicobacter pylori infection. *Best Practice & Research Clinical Gastroenterology* Vol. 21, No. 2, pp. 237–259, 2007
17. Wadhwa R et al. Gastric Cancer - molecular and clinical dimensions. *Nature Reviews Clinical Oncology* 10, 643–655 (2013)
18. H pylori infection. Tests and diagnosis. Mayo Clinic. Available at: <http://www.mayoclinic.org/diseases-conditions/h-pylori/basics/tests-diagnosis/con-20030903>. Accessed October 2015
19. H pylori infection workup. Laboratory Studies. Available at: <http://emedicine.medscape.com/article/176938-workup>. Accessed October 2015
20. National Cancer Institute. Helicobacter Pylori and Cancer. Available at: <http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet>. Accessed October 2015
21. World Cancer Fund International. Stomach Cancer Statistics. Available at: <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/stomach-cancer-statistics>. Accessed October 2015
22. Lin Y et al. Comparative epidemiology of gastric cancer between Japan and China. *World J Gastroenterol.* 2011 Oct 21; 17(39): 4421–4428.
23. China National Cancer Institute. Western rates are estimated at ~85%
24. H. Ono, H. Kondo, T. Gotoda, et al., “Endoscopic mucosal resection for treatment of early gastric cancer,” *Gut*, vol. 48, no. 2, pp. 225–229, 2001.
25. Source: GLOBOCAN 2012, World Health Organisation. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed November 2015
26. Olbermann P et al. A Global Overview of the Genetic and Functional Diversity in the Helicobacter pylori cag Pathogenicity Island. *PLOS Genetics.* August 19, 2010
DOI: 10.1371/journal.pgen.1001069
27. Peptic Ulcer Disease. *Emedicine – Medscape.* Available at: <http://emedicine.medscape.com/article/181753-overview#a7>. Accessed October 2015
28. Majumdar D et al. Helicobacter pylori infection and peptic ulcers. 2007. *Medicine* 35:4
29. Manuel D et al. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications. 2007. *Aliment Pharmacol Ther* 25, 1423–1427
30. H pylori infection. Tests and diagnosis. Mayo Clinic. Available at: <http://www.mayoclinic.org/diseases-conditions/h-pylori/basics/tests-diagnosis/con-20030903>. Accessed October 2015
31. H pylori infection workup. Laboratory Studies. Available at: <http://emedicine.medscape.com/article/176938-workup>. Accessed October 2015

32. American College of Gastroenterology. Management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007;102:1808–1825
33. Meyer JM, Silliman NP, Wang W, et al. Risk factors for *Helicobacter pylori* resistance in the United States: The surveillance of *H. pylori* antimicrobial resistance partnership (SHARP) study, 1993–1999. *Ann Intern Med* 2002;136:13–24.
34. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: Importance of CagA status for successful eradication of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2006;24:273–80.
35. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. *Gastroenterology* 2009;136:376–386
36. Perry AF et al. Burden of Gastrointestinal Disease in the United States: 2012 Update. *Gastroenterology* 2012;143:1179–1187
37. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. *Am J Gastroenterol* 1997;92:614–620.
38. The Global Use of Medicines: Outlook through 2017. IMS Institute For Healthcare Informatics. November 2015
39. Del Giudice, G.; Covacci, A.; Telford, J.L.; Montecucco, C.; Rappuoli, R. The design of vaccines against *Helicobacter pylori* and their development. *Annu. Rev. Immunol.* 2001, 19, 523–563.
40. Nystrom, J.; Svennerholm, A.M. Oral immunization with HpaA affords therapeutic protective immunity against *H. pylori* that is reflected by specific mucosal immune responses. *Vaccine* 2007, 25, 2591–2598
41. Every, A.L.; Stent, A.; Moloney, M.B.; Ng, G.Z.; Skene, C.D.; Edwards, S.J.; Sutton, P. Evaluation of superoxide dismutase from *Helicobacter pylori* as a protective vaccine antigen. *Vaccine* 2011, 29, 1514–1518
42. Muller, A. & Solnick, J. V. Inflammation, immunity, and vaccine development for *Helicobacter pylori*. *Helicobacter* 16 (Suppl. 1), 26–32 (2011).
43. Ruggiero P et al. *Helicobacter pylori* : A Brief history of a Still lacking vaccine. *Diseases* 2014, 2, 187–208
44. Lewis, D.J.; Huo, Z.; Barnett, S.; Kromann, I.; Giemza, R.; Galiza, E.; Woodrow, M.; Thierry-Carstensen, B.; Andersen, P.; Novicki, D.; et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of *Escherichia coli* heat labile toxin. *PLoS One* 2009, 4, e6999.
45. Kotloff, K.L.; Sztein, M.B.; Wasserman, S.S.; Losonsky, G.A.; Di Lorenzo, S.C.; Walker, R.I. Safety and immunogenicity of oral inactivated whole-cell *Helicobacter pylori* vaccine with adjuvant among volunteers with or without subclinical infection. *Infect. Immun* 2001, 69, 3581–3590.
46. Michetti, P.; et al. Oral immunization with urease and *Escherichia coli* heat-labile enterotoxin is safe and immunogenic in *Helicobacter pylori*-infected adults. *Gastroenterology* 1999, 116, 804–812
47. Di Petrillo, M.D et al. Safety and immunogenicity of phoP/phoQ-deleted *Salmonella typhi* expressing *Helicobacter pylori* urease in adult volunteers. *Vaccine* 1999, 18, 449–459.
48. Malfetheriner, P et al. Safety and immunogenicity of an intramuscular *Helicobacter pylori* vaccine in noninfected volunteers: A phase I study. *Gastroenterology* 2008, 135, 787–795.
49. Malfetheriner P et al. Efficacy of an investigational recombinant antigen based vaccine against CagA *H. pylori* infectious challenge in healthy volunteers. *Gastroenterology*. 2012; 142:2: S 184
50. Zeng M et al. Efficacy, safety, and immunogenicity of an oral recombinant *Helicobacter pylori* vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet* 2015. Volume 386, No. 10002, p1457–1464, 10 October 2015
51. Sutton P. At last, vaccine-induced protection against *H. pylori*. *Lancet*. Published Online July 1, 2015 S0140-6736(15)60579-7
52. Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of *Escherichia coli* heat labile toxin. *PLoS One* 2009; 4: e6999.
53. China's Stomach Cancer Vaccine To Hit The Market Next Year. *China Bio Today*. June 15, 2010. Available at: <http://www.istockanalyst.com/article/viewarticle/articleid/4216326>. Accessed October 2015
54. i+o plans new production facility for KangWei Biotech in China to commercialize *Helicobacter pylori* vaccine. Shanghai 2012. Available at: <http://www.io-consultants.com/io/en/news/detail/ne/i-o-plans-new-production-facility-for-kangwei-biotech-in-china-to-commercialize-helicobacter-pylori/>. Accessed October 2015
55. Stomach new drug is eligible for State Technological Invention Award in the first half of this year is expected to pilot production. *Chongqing News Portal*. Available at: http://cq.cqnews.net/html/2014-01/10/content_29389469.htm. Accessed October 2015
56. Imevax. Immune Evasion Vaccines. Available at: <http://www.imevax.com/about-us/> Accessed November 2015
57. *H. pylori* vaccine the target of \$575,000 collaboration. Available at: <http://www.labcanada.com/news/h-pylori-vaccine-the-target-of-575-000-collaboration/1003453828/?&er=NA> Accessed November 2015
58. Funds support work being conducted at Sudbury medical research institute AMRIC. Available at: <http://www.northernlife.ca/news/localNews/2015/10/39-amric-nohfc-funding-cancer-vaccine-sudbury.aspx> Accessed November 2015
59. EpiVax Is Awarded *H. Pylori* SBIR Grant by National Institutes of Health. *Epivax corporate website*. Available at: <http://www.epivax.com/news/epivax-is-awarded-h-pylori-sbir-grant-by-national-institutes-of-health/>. November 2015
60. Zhang S et al. Human Immune Responses to *H. pylori* HLA Class II Epitopes Identified by Immunoinformatic Methods. *PLoS ONE* 9(4): e94974. doi:10.1371/journal.pone.0094974

61. Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st century: a tool for decisionmaking. Committee to Study Priorities for Vaccine Development. Washington, DC: National Academies Press. p. 476.
62. Rupnow MF et al. Cost-Effectiveness of a Potential Prophylactic Helicobacter pylori Vaccine in the United States. The Journal of Infectious Diseases 2009; 200:1311–17
63. Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008; 43:1448–55. 29.
64. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17:838–45.
65. US Census Bureau. International Database (IDB). Available at: <http://www.census.gov/ipc/www/idb/index.php>. Accessed November 2015
66. WHO. Immunization surveillance, assessment and monitoring. Available at: http://www.who.int/immunization/monitoring_surveillance/en/. Accessed November 2015
67. The GAVI alliance. Human papillomavirus vaccine support. Available at: <http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/>. Accessed November 2013
68. Sandler RS et al. The Burden of Selected Digestive Diseases in the United States. GASTROENTEROLOGY 2002;122:1500–1511
69. Feinstein LB et al. Trends in Hospitalizations for Peptic Ulcer Disease, United States, 1998–2005. Volume 16, Number 9—September 2010
70. Refs within Sung JJY et al. Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary Pharmacology & Therapeutics. Volume 29, Issue 9, pages 938–946, May 2009
71. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole in the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328: 308-312. [PubMed]

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009